Navigation Links
Imperial Tobacco - 2010 Half Year Results Interviews
Date:4/27/2010

LONDON, April 27, 2010 /PRNewswire-FirstCall/ -- Imperial Tobacco today announces strong half year results against a challenging market backdrop. In a video interview with online financial broadcaster http://www.cantos.com, Chief Executive Gareth Davis states, "it's been a very good first half which demonstrates the resilience of our business and the success of our enhanced focus on sales".

Davis hands over the reins of the leading international tobacco company to Chief Operating Officer Alison Cooper next month and says the Board couldn't have chosen a more able successor.

"Alison's leadership qualities, her experience and her drive and energy will ensure that the business is driven forward, taking advantage of our portfolio, our operating platform and the skills of the people that we have."

The interview and transcript are available now on http://www.cantos.com.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE Imperial Tobacco Group PLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. KAUST announces academic excellence alliance partnership with Imperial College London
2. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
3. Does the desire to consume alcohol and tobacco come from our genetic makeup?
4. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
5. Your babys brain on drugs (and alcohol and tobacco)
6. UT researchers find link between advertising and increased tobacco use among Indias youth
7. Infection blocks lungs protective response against tobacco smoke
8. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
9. Tobacco makes medicine
10. Women more vulnerable to tobacco carcinogens, new results show
11. Novel mechanism revealed for increasing recombinant protein yield in tobacco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology: